Back to Results
First PageMeta Content
Pharmacology / Monoclonal antibodies / Adalimumab / Autoimmune diseases / Rheumatoid arthritis / Latent tuberculosis / Disease-modifying antirheumatic drug / Biologic / Placebo / Medicine / Immunosuppressants / Immunology


Adalimumab (HUMIRA) - package insert
Add to Reading List

Open Document

File Size: 69,55 KB

Share Result on Facebook

Company

Ames / /

Facility

American College of Rheumatology / /

IndustryTerm

drug product / phage display technology / preservative-free solution / /

MedicalCondition

anaphylactic reaction / demyelinating disease / allergic reaction / pneumonia / latent tuberculosis infection / lymphoma / disease / Carcinogenesis / bronchitis / rheumatoid arthritis / chronic / demyelinating disorders / erythema / itching / fever / respiratory tract infections / human tumor necrosis factor / pathologic inflammation / normal inflammatory and immune responses / hypersensitivity / infection / urinary tract infections / active rheumatoid arthritis / cough / inflammation / depression / INFECTIONS / rash / syndrome / tuberculosis / /

MedicalTreatment

Immunosuppression / Immunizations / vaccination / /

Organization

HUMIRA administration / World Health Organization / American College of Rheumatology / Centers for Disease Control and Prevention / /

Person

Tuberculosis As / /

Position

Physician / General / pH. CLINICAL PHARMACOLOGY General / /

Product

HUMIRA / sodium chloride / mannitol / /

Technology

alpha / Pharmacokinetics / X-ray / antibodies / Pharmacodynamics / recombinant DNA technology / using phage display technology / /

SocialTag